Jose Halperin

JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA.

NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC.

Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell.

Gila Therapeutics, Inc. provides developing therapies for obesity patients. The company was founded by Sergei Zolotukhin and Andres Acosta in January 2014 and is headquartered in Excelsior, MN.

Part of Novartis AG, Novartis, Inc. is a company based in San Francisco.

Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA.

Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts.

Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom.

Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA.

Laureate Biopharmaceutical Services, Inc. provides biopharmaceutical development and protein production services. It offers product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The firm's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply. The company was founded in 1981 and is headquartered in Princeton, NJ.

HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.